Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company focused on developing innovative therapies for a range of cancers, including both rare and common types. The company has a diverse clinical pipeline featuring several promising candidates, including zilovertamab, a humanized monoclonal antibody targeting ROR1, and ONCT-216, a small molecule designed to inhibit ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a CAR-T product targeting ROR1, and ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer. By employing a variety of therapeutic strategies, including antibodies, antibody-drug conjugates, small molecules, and CAR-T technologies, Oncternal Therapeutics seeks to address significant unmet medical needs in oncology through highly targeted treatments.
GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.